These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35088591)

  • 21. Clinical effect of captopril on the formation and growth of cystine calculi.
    Cohen TD; Streem SB; Hall P
    J Urol; 1995 Jul; 154(1):164-6. PubMed ID: 7776415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How should patients with cystine stone disease be evaluated and treated in the twenty-first century?
    Andreassen KH; Pedersen KV; Osther SS; Jung HU; Lildal SK; Osther PJ
    Urolithiasis; 2016 Feb; 44(1):65-76. PubMed ID: 26614112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis.
    Worcester EM; Coe FL; Evan AP; Parks JH
    BJU Int; 2006 Jun; 97(6):1285-90. PubMed ID: 16686727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of long-term treatment of cystine lithiasis with D-penicillamine].
    Bec P; Lacombe JL; Malha F; Pujo JM
    Nephrologie; 1984; 5(5):228-31. PubMed ID: 6531062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine.
    Martins MC; Meyers AA; Whalley NA; Rodgers AL
    J Urol; 2002 Jan; 167(1):317-21. PubMed ID: 11743349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical course and cystine stone formation during tiopronin treatment.
    Lindell A; Denneberg T; Hellgren E; Jeppsson JO; Tiselius HG
    Urol Res; 1995; 23(2):111-7. PubMed ID: 7676533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The advances of calcium oxalate calculi associated drugs and targets.
    Lai Y; Zheng H; Sun X; Lin J; Li Q; Huang H; Hou Y; Zhong H; Zhang D; Fucai T; He Z
    Eur J Pharmacol; 2022 Nov; 935():175324. PubMed ID: 36257382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro effects on calcium oxalate crystallization kinetics and crystal morphology of an aqueous extract from Ceterach officinarum: Analysis of a potential antilithiatic mechanism.
    De Bellis R; Piacentini MP; Meli MA; Mattioli M; Menotta M; Mari M; Valentini L; Palomba L; Desideri D; Chiarantini L
    PLoS One; 2019; 14(6):e0218734. PubMed ID: 31238335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystine Stone Formers Have Impaired Health-Related Quality of Life Compared with Noncystine Stone Formers: A Case-Referent Study Piloting the Wisconsin Stone Quality of Life Questionnaire Among Patients with Cystine Stones.
    Streeper NM; Wertheim ML; Nakada SY; Penniston KL
    J Endourol; 2017 Apr; 31(S1):S48-S53. PubMed ID: 27717296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of crystal surface adhesion in kidney stone disease.
    Wesson JA; Ward MD
    Curr Opin Nephrol Hypertens; 2006 Jul; 15(4):386-93. PubMed ID: 16775453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes for Cystinuria Patients with Unilateral Versus Bilateral Cystine Stone Disease.
    Usawachintachit M; Sherer B; Hudnall M; Tzou DT; Taguchi K; Hsi RS; Stoller M; Chi T
    J Endourol; 2018 Feb; 32(2):148-153. PubMed ID: 29179563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel cystine ester mimics for the treatment of cystinuria-induced urolithiasis in a knockout mouse model.
    Sahota A; Parihar JS; Capaccione KM; Yang M; Noll K; Gordon D; Reimer D; Yang I; Buckley BT; Polunas M; Reuhl KR; Lewis MR; Ward MD; Goldfarb DS; Tischfield JA
    Urology; 2014 Nov; 84(5):1249.e9-15. PubMed ID: 25443947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization.
    Su Y; Li S; Li X; Zhou JY; Chauhan VP; Li M; Su YH; Liu CM; Ren YF; Yin W; Rimer JD; Cai T
    Adv Sci (Weinh); 2024 Jun; 11(21):e2400642. PubMed ID: 38647258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation.
    Sheng X; Ward MD; Wesson JA
    J Am Soc Nephrol; 2005 Jul; 16(7):1904-8. PubMed ID: 15930089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological interventions for the management of cystinuria: a systematic review.
    Bhatt NP; Deshpande AV; Starkey MR
    J Nephrol; 2024 Mar; 37(2):293-308. PubMed ID: 37957454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What does the crystallography of stones tell us about their formation?
    Rez P
    Urolithiasis; 2017 Feb; 45(1):11-18. PubMed ID: 27900406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular modifiers reveal a mechanism of pathological crystal growth inhibition.
    Chung J; Granja I; Taylor MG; Mpourmpakis G; Asplin JR; Rimer JD
    Nature; 2016 Aug; 536(7617):446-50. PubMed ID: 27501150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preventive measures in stones due to infection, uric acid and cystine].
    Hess B; Ackermann D
    Ther Umsch; 1992 Jan; 49(1):44-8. PubMed ID: 1736401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphological characteristics and microstructure of kidney stones using synchrotron radiation μCT reveal the mechanism of crystal growth and aggregation in mixed stones.
    Manzoor MAP; Agrawal AK; Singh B; Mujeeburahiman M; Rekha PD
    PLoS One; 2019; 14(3):e0214003. PubMed ID: 30901364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.